This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 1999;282:1905-1906.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

San Francisco—The first experimental pneumococcal vaccine designed for young children—Prevenar (Wyeth-Lederle, Philadelphia)—appears to substantially reduce childhood cases of pneumonia, according to a new study aired here at a recent meeting of infectious disease experts.

The vaccine is a pneumococcal conjugate vaccine that targets the seven strains of Streptococcus pneumoniae that are responsible for 85% of bacterial pneumonia in children, explained Steven Black, MD, of the Kaiser Permanente Vaccine Study Center in Oakland, Calif, who reported the results of the new study. The pneumococcal vaccine currently recommended for people over age 65 is formulated against other strains of the bacterium.

APPROVAL RECOMMENDED

At a meeting in Bethesda, Md, on November 5, an Advisory Committee reviewed the data from the efficacy trial on Prevenar and unanimously agreed that the 7-valent pneumococcal conjugate vaccine is effective. Robert S. Daum, MD, of the University of Chicago Children's Hospital, called its . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?